Ocrelizumab dose selection for treatment of relapsing-remitting multiple sclerosis in children and adolescents: Preliminary pharmacokinetic, safety and efficacy results from the OPERETTA 1 study

M. Valeriani,S. Mar, B. Steinborn,T. Schreiner,E. Waubant, M. Filippi, C. Manlius,H. Kletzl, C. -J. Lin,D. Zecevic, A. Hogea, J. Evershed,B. Banwell

MULTIPLE SCLEROSIS JOURNAL（2022）

Cited 0|Views10

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined